Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H26O6 |
| Molecular Weight | 386.4382 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1
InChI
InChIKey=VWVKUNOPTJGDOB-BDHVOXNPSA-N
InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1
| Molecular Formula | C22H26O6 |
| Molecular Weight | 386.4382 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
509 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
344 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
444 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1020 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
742 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1050 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
310 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
220 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
506 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
394 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1210 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1930 ng/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1570 ng/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3710 ng/mL |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6740 ng/mL |
320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11900 ng/mL |
640 mg single, oral dose: 640 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
69.3 ng/mL |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
59.9 ng/mL |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
484 ng/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
391 ng/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1810 ng/mL |
80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1660 ng/mL |
80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
35.6 ng/mL |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
36.7 ng/mL |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
89.4 ng/mL |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
77 ng/mL |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
355 ng/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
340 ng/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
939 ng/mL |
60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1000 ng/mL |
60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2030 ng/mL |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1610 ng/mL |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
410 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
391 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
399 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
360 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1230 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
846 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2140 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1990 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
1890 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4190 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3690 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3730 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1330 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1040 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1900 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1820 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5640 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
8830 ng × h/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7090 ng × h/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
21800 ng × h/mL |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
38100 ng × h/mL |
320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
99100 ng × h/mL |
640 mg single, oral dose: 640 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
204 ng × h/mL |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
192 ng × h/mL |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1680 ng × h/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1550 ng × h/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7240 ng × h/mL |
80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6740 ng × h/mL |
80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
184 ng × h/mL |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
179 ng × h/mL |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
380 ng × h/mL |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
387 ng × h/mL |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1500 ng × h/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1380 ng × h/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4620 ng × h/mL |
60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4740 ng × h/mL |
60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
10900 ng × h/mL |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9690 ng × h/mL |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1740 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2070 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2040 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1970 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6720 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3830 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.4 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.82 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
5.65 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.39 h |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.48 h |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
5.65 h |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.71 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.09 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.29 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.7 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.77 h |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.73 h |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.36 h |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.63 h |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.53 h |
320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.06 h |
640 mg single, oral dose: 640 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.37 h |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.35 h |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.14 h |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.64 h |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.07 h |
80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
17 h |
80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.71 h |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.08 h |
2.5 mg 1 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.19 h |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.8 h |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.75 h |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.34 h |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.74 h |
60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.44 h |
60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.98 h |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.75 h |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.21 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.65 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.06 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.52 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9.01 h |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.5 h |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.4% |
TOFOGLIFLOZIN plasma | Homo sapiens |
||
16.9% |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
15.1% |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
15.6% |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
19.7% |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOFOGLIFLOZIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
640 mg single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
Disc. AE: Weight decrease... AEs leading to discontinuation/dose reduction: Weight decrease (grade 2, 1.7%) Sources: |
80 mg 1 times / day multiple, oral Studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Weight decrease | grade 2, 1.7% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. | 2013-04 |
|
| Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. | 2013-02-15 |
|
| Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. | 2012-09-13 |
|
| Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. | 2012-06 |
Patents
Sample Use Guides
In general, for adults, take 20 mg of tofogliflozin once a day, before or after breakfast.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:57:20 GMT 2025
by
admin
on
Mon Mar 31 19:57:20 GMT 2025
|
| Record UNII |
554245W62T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98083
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
554245W62T
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
PRIMARY | |||
|
903565-83-3
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
PRIMARY | |||
|
C152676
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
PRIMARY | |||
|
SUB177215
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
PRIMARY | |||
|
46908929
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
PRIMARY | |||
|
DTXSID90238097
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
PRIMARY | |||
|
m11867
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
PRIMARY | |||
|
100000163089
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
PRIMARY | |||
|
9275
Created by
admin on Mon Mar 31 19:57:20 GMT 2025 , Edited by admin on Mon Mar 31 19:57:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
20.4 EXCRETED IN FECES
MAJOR
FECAL
|
||
|
METABOLITE INACTIVE -> PARENT |
76% OF TOTAL DOSE EXCRETED IN URINE;
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
PERCENT OF TOTAL DOSE
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
PERCENT OF AUC
PLASMA
|
||
|
METABOLITE INACTIVE -> PARENT |
TAKEN FROM AUC
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
PERCENT OF TOTAL DOSE
FECAL
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
